Viewpoint: Multiple Schedule II Rxs: Road to disaster?
DEA's new rule allowing multiple prescriptions for Schedule II controlled substances could engender greater Rx drug abuse.
Background to DEA change
Implications for pharmacists
Everyone knows that prescription drug abuse is increasing. We may be in the minority, but we strongly feel that there should be more restrictive prescribing measures put into place, especially for Schedule II controlled substances, rather than more leniency, which, we believe, the final rule promotes. Methadone-related deaths have been growing. DEA is concerned about these rising statistics, but it does not set up any limitations on methadone prescribing under these regulations. Is this appropriate?
It is disappointing to realize that as deaths are rising from prescription drug abuse, DEA would pass a rule that would only compound the problem. Pharmacists should voice their concerns about this ruling so that it is reversed.
JENNIFER FASS is a drug information resident, and MATTHEW SEAMON is assistant professor at Nova Southeastern University, College of Pharmacy, Fort Lauderdale, Fla.
Pharmacists Play Unique Role in Advancing Health Equity for Patients With Chronic Disease
December 7th 2023A new study, outlined in a poster at ASHP Midyear 2023, identified 3 key themes associated with the ways in which pharmacists are positioned to advance health equity for patients with chronic diseases.
